Clinical Study on Infliximab for Treating Refractory Ulcerative Colitis
10.3969/j.issn.1008-7125.2014.12.007
- VernacularTitle:英夫利西单抗治疗难治性溃疡性结肠炎的临床研究
- Author:
Hui XING
;
Xiaolan YANG
;
Yanyan SONG
;
Chenshuang KONG
- Publication Type:Journal Article
- Keywords:
Infliximab;
Colitis,Ulcerative;
Therapy
- From:Chinese Journal of Gastroenterology
2014;(12):734-735
- CountryChina
- Language:Chinese
-
Abstract:
Background:Patients with refractory ulcerative colitis( UC ) cannot benefit from the conventional aminosalicylic acids,steroids and immunosuppressants. The emergence of biological agents offers new opportunities for these patients. Aims:To evaluate the clinical efficacy of infliximab for treating patients with refractory UC. Methods:Twelve patients with moderate to severe active UC admitted from Dec. 2012 to Jan. 2014 at the Second Affiliated Hospital of Harbin Medical University were retrospectively enrolled. All of them were steroids-refractory or steroids-dependent and infliximab therapy was then administered. Modified Mayo score was used to evaluate the disease activity and the efficacy of infliximab. Results:All patients completed the infliximab therapy and a 38-week follow-up. After treatment,the clinical manifestations were improved with varying degrees,and the efficacy at the 6th,22nd and 38th weeks was 66. 7%,83. 3% and 91. 7%, respectively,with significant differences between any two time points(P﹤0. 05). Conclusions:Infliximab is effective and practical for the treatment of refractory UC.
